1610413-96-1
Chemical Structure
EC1169
- CAS No.: 1610413-96-1
- Formula:C78H112N14O28S3
- Molecular Weight:1790.00
IUPAC Name: (9S,13S)-1-(4-((3R,5S,16R,19S,22S)-1-(2-((1R,3R)-1-acetoxy-3-((2S,3S)-N-((butyryloxy)methyl)-3-methyl-2-((R)-1-methylpiperidine-2-carboxamido)pentanamido)-4-methylpentyl)thiazol-4-yl)-16-carboxy-19,22-bis(carboxymethyl)-3-(4-hydroxybenzyl)-5-methyl-1,6,9,18,21,24-hexaoxo-10-oxa-13,14-dithia-2,7,8,17,20,23-hexaazapentacosan-25-yl)phenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
InChIKey: FHMWPGDRYQRIPB-IEAKDTJSSA-N
SMILES: O=C([C@@H]1N(CCCC1)C)N[C@@H]([C@@H](C)CC)C(N(COC(CCC)=O)[C@@H](C(C)C)C[C@H](C2=NC(C(N[C@H](C[C@H](C)C(NNC(OCCSSC[C@@H](C(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC(CC3=CC=C(C=C3)CNC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)=O)=O)=O)CC4=CC=C(C=C4)O)=O)=CS2)OC(C)=O)=O
Biological Activity: EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
EC1169 | 98.06% | EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang T, et al. Small Molecule-Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment. Mol Pharm. 2024;21(3):1038-1055. [Content Brief]
- [2]. Reddy J A, et al. PSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169[J]. Cancer research, 2013, 73(8_Supplement): 2145-2145.
- [3]. Leamon C P, et al. Prostate-specific membrane antigen-specific antitumor activity of a self-immolative tubulysin conjugate[J]. Bioconjugate Chemistry, 2019, 30(6): 1805-1813.
